In Silico Identification of a Potent Arsenic Based Approved Drug Darinaparsin against SARS-CoV-2:  Inhibitor of RNA dependent RNA polymerase (RdRp) and Necessary Proteases

Trinath Chowdhury; Gourisankar Roymahapatra; Santi M Mandal

doi:10.26434/chemrxiv.12200495.v1

Biological and Medicinal Chemistry

Search within Biological and Medicinal Chemistry

In Silico Identification of a Potent Arsenic Based Approved Drug Darinaparsin against SARS-CoV-2: Inhibitor of RNA dependent RNA polymerase (RdRp) and Necessary Proteases

28 April 2020, Version 1

Working Paper

Show author details

This content is a preprint and has not undergone peer review at the time of posting.

Abstract

The work demonstrate screening of several arsenical compounds against RdRp of coronavirus. The study implies out of all arsenical compounds, darinaparsin shows its most effective results based on in silico docking analysis. This study also confirmed the significant interaction between the active site of viral replicase protein, endoribonuclease protein and different proteases with darinaparsin.

Keywords

COVID-19

Arsenical drug

Darinaparsin

RNA dependent RNA polymerase

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here .

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Version History

Apr 28, 2020 Version 1

Metrics

5,697

1,043

Views

Downloads

License

The content is available under CC BY NC ND 4.0

DOI

10.26434/chemrxiv.12200495.v1

Author’s competing interest statement

There is no conflct of interest between the authors.